Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc. (RPHM) Stock Overview
Explore Reneo Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
RPHM Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Reneo Pharmaceuticals, Inc. (RPHM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $20.53.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 22.18 and a market capitalization of 60.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Gregory J. Flesher
8
18575 Jamboree Road, Irvine, CA
2021